Literature DB >> 7516658

Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E.

I W Althaus1, J J Chou, A J Gonzales, M R Deibel, K C Chou, F J Kezdy, D L Romero, R C Thomas, P A Aristoff, W G Tarpley.   

Abstract

The bisheteroarylpiperazine U-90152E is a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) and possesses excellent anti-HIV activity in HIV-1-infected lymphocytes grown in tissue culture. The compound inhibits both the RNA- and DNA-directed DNA polymerase functions of HIV-1 RT. Kinetic studies were carried out to elucidate the mechanism of RT inhibition by U-90152E. Michaelis-Menten kinetics, which are based on the establishment of a rapid equilibrium between the enzyme and its substrates, proved inadequate for the analysis of the experimental data. The data were thus analyzed using Briggs-Haldane kinetics, assuming that the reaction is ordered in that the template:primer binds to the enzyme first, followed by the addition of dNTP and that the polymerase is a processive enzyme. Based on these assumptions, a velocity equation was derived, which allows the calculation of all the essential forward and backward rate constants for the reactions occurring between the enzyme, its substrates and the inhibitor. The results obtained indicate that U-90152E acts exclusively as a mixed inhibitor with respect to the template: primer and dNTP binding sites for both the RNA- and DNA-directed DNA polymerase domains of the enzyme. The inhibitor shows a significantly higher binding affinity for the enzyme-substrate complexes than for the free enzyme and consequently does not directly impair the functions of the substrate binding sites. Therefore, U-90152E appears to impair an event occurring after the formation of the enzyme-substrate complexes, which involves either inhibition of the phosphoester bond formation or translocation of the enzyme relative to its template:primer following the formation of the ester bond.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516658     DOI: 10.1016/0006-2952(94)90077-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  18 in total

1.  Determination of the composition of delavirdine mesylate polymorph and pseudopolymorph mixtures using 13C CP/MAS NMR.

Authors:  P Gao
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

Review 2.  Structural Variability in the RLR-MAVS Pathway and Sensitive Detection of Viral RNAs.

Authors:  Qiu-Xing Jiang
Journal:  Med Chem       Date:  2019       Impact factor: 2.745

Review 3.  Delavirdine: a review of its use in HIV infection.

Authors:  L J Scott; C M Perry
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

4.  Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA.

Authors:  Elena N Peletskaya; Alex A Kogon; Steven Tuske; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

5.  Characterization of three crystalline forms (VIII, XI, and XII) and the amorphous form (V) of delavirdine mesylate using 13C CP/MAS NMR.

Authors:  P Gao
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

6.  Effect of reverse transcriptase inhibitors on LINE-1 and Ty1 reverse transcriptase activities and on LINE-1 retrotransposition.

Authors:  Lixin Dai; Qing Huang; Jef D Boeke
Journal:  BMC Biochem       Date:  2011-05-05       Impact factor: 4.059

7.  iACP: a sequence-based tool for identifying anticancer peptides.

Authors:  Wei Chen; Hui Ding; Pengmian Feng; Hao Lin; Kuo-Chen Chou
Journal:  Oncotarget       Date:  2016-03-29

8.  iHyd-PseCp: Identify hydroxyproline and hydroxylysine in proteins by incorporating sequence-coupled effects into general PseAAC.

Authors:  Wang-Ren Qiu; Bi-Qian Sun; Xuan Xiao; Zhao-Chun Xu; Kuo-Chen Chou
Journal:  Oncotarget       Date:  2016-07-12

9.  Prediction of HIV-1 and HIV-2 proteins by using Chou's pseudo amino acid compositions and different classifiers.

Authors:  Juan Mei; Ji Zhao
Journal:  Sci Rep       Date:  2018-02-05       Impact factor: 4.379

10.  iSS-PseDNC: identifying splicing sites using pseudo dinucleotide composition.

Authors:  Wei Chen; Peng-Mian Feng; Hao Lin; Kuo-Chen Chou
Journal:  Biomed Res Int       Date:  2014-05-21       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.